CoChat

Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide

Open access
Fonseca, Vivian A, Capehorn, Matthew S, Garg, Satish K, Jódar Gimeno, Esteban, Hansen, Oluf H, Holst, Anders G, Nayak, Gurudutt, Seufert, Jochen · 2019 · The Journal of Clinical Endocrinology & Metabolism
Cited by 63

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Context: Semaglutide, a once-weekly glucagon-like peptide-1 analog approved for use in patients with type 2 diabetes (T2D), demonstrated superior body weight (BW) reductions and decreased insulin resistance (IR) vs comparators across the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) 1–3 clinical trials. Objective: To investigate the relationship between IR and BW across the SUSTAIN 1–3 trials. Design: Post hoc analysis of the SUSTAIN 1–3 trials. Setting: Three hundred and eleven sites in 30 countries. Patients or other participants: 2432 subjects with T2D. Interventions: Semaglutide 0.5 or 1.0 mg, placebo or active comparator (sitagliptin 100 mg, exenatide extended release 2.0 mg). Main Outcome Measure: To assess the extent of the effect on IR that is mediated (indirect effect) and not mediated (direct effect) by the effect on BW. Results: Across SUSTAIN 1–3, mean BW was significantly reduced with semaglutide 0.5 mg (3.7 kg to 4.3 kg; P < 0.0001) and semaglutide 1.0 mg (4.5 kg to 6.1 kg; P < 0.0001) vs comparators (1.0 kg to 1.9 kg). There were greater reductions in IR with semaglutide 0.5 mg (27% to 36%) and semaglutide 1.0 mg (32% to 46%) vs comparators (17% to 28%). Greater reductions in BW were generally associated with greater decreases in IR. The effect on IR was primarily mediated by weight loss (70% to 80% and 34% to 94%, for semaglutide 0.5 mg and 1.0 mg, respectively, vs comparator). Conclusions: Semaglutide consistently reduced BW and IR in subjects with T2D in SUSTAIN 1–3. In this analysis, IR improvement was positively associated with, and primarily mediated by, the effect of semaglutide on BW.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2018-02685

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 63

Metadata

Authors
Fonseca, V. A., Capehorn, M. S., Garg, S. K., Jódar Gimeno, E., Hansen, O. H., Holst, A. G., Nayak, G., & Seufert, J.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2019-04-02
Volume
104
Issue
9
Pages
4078-4086
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2929875152
Cited by
63
References
15
FWCI
3.61
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. https://app.cochat.ai/papers/10.1210/jc.2018-02685
The paper
Fonseca, V. A., Capehorn, M. S., Garg, S. K., Jódar Gimeno, E., Hansen, O. H., Holst, A. G., Nayak, G., & Seufert, J. (2019). Reductions in Insulin Resistance are Mediated Primarily via Weight Loss in Subjects With Type 2 Diabetes on Semaglutide. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-02685

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.